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I. INTRODUCTION 
Herpesviruses are enveloped, double stranded DNA viruses, which are widely spread in 
nature infecting an immense variety of host species from bivalves to humans. More than 
130 species have been discovered so far (BROWN & NEWCOMB, 2011), closely co-
evolved with their host species over time and thus symbolizing an impressive example of 
coevolutionary success. This highly efficient host adaptation is clearly demonstrated by the 
key characteristic of all herpesviruses: the ability to establish a chronic persistent infection 
called latency, which symbolizes a perfect coexistence in balance with the host immune 
system (DAVISON, 2002). From a clinical and economical point of view, Equid 
Herpesvirus 1 (EHV-1) is the most relevant herpesvirus affecting horses worldwide as it 
can cause respiratory disease, equid herpesvirus myeloencephalopathy (EHM), abortions 
and neonatal foal death. Following initial EHV-1 infection, the virus replicates in the upper 
respiratory tract (URT) epithelium and subsequently enters the blood circulation by infect-
ing mononuclear cells. The virus is then transported to secondary infection sites like central 
nervous system (CNS) or uterus endothelium during cell-associated viremia where it can 
cause secondary disease manifestations (EHM, abortion) (HUSSEY et al., 2006; 
GOEHRING et al., 2010b; WILSTERMAN et al., 2011; SLATER, 2014). As the currently 
available vaccines or treatment options can only possibly ameliorate but not fully prevent 
EHV-1 disease outbreaks, strict biosecurity measures including quarantine and travel re-
strictions represent the most effective prevention strategies, however, with significant eco-
nomic impact (LUNN et al., 2009; GOEHRING et al., 2010c). Like its close human path-
ogen relatives, Herpes Simplex Virus 1 (HSV-1) and Varicella Zoster Virus (VZV), EHV-1 
is highly prevalent in the host population with presumably > 60 % of horses being latently 
infected (EDINGTON et al., 1994; LUNN et al., 2009). Most importantly, latently infected 
horses, where the virus can reactivate at any given time, are the main source for new infec-
tions, possibly resulting in new outbreaks. Although EHV-1 has been studied for years, the 
details of latency establishment and reactivation are still not well understood (SLATER, 
2014). The current understanding is that similar to its close relatives HSV-1, VZV and 
Bovine Herpesvirus 1 (BoHV-1), EHV-1 enters sensory nerve endings in the vicinity of 
the URT epithelium and reaches the trigeminal ganglia (TG) via neuronal transport for 
latency establishment (GILDEN et al., 1983; SLATER et al., 1994; EFSTATHIOU & 
PRESTON, 2005). Furthermore, latent EHV-1 has been repeatedly detected in respiratory 
tract-associated lymphoid tissue (RALT) and in circulating mononuclear cells (WELCH et 
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al., 1992; EDINGTON et al., 1994; CHESTERS et al., 1997; SMITH et al., 1998). During 
latency, the virus persists within the host cell nucleus in a non-infectious state with limited 
viral gene transcription. However, little is known about the molecular mechanisms that are 
involved in establishment and regulation of latency.  
Our main goal is to limit further EHV-1 outbreaks. As it is unlikely to prevent initial 
EHV-1 infection, research approaches need to focus on finding potential strategies to con-
trol EHV-1 in its latent state. Therefore, the short-term goal of this dissertation is to further 
characterize EHV-1 latency pathogenesis following experimental infection of the natural 
host. The main study presented in this dissertation is based on previous findings of our 
research group (SAMOILOWA, 2019): Interestingly, at a time point beyond viremia 
(70 days post infection (dpi)), EHV-1 DNA was detected not only in TG and RALT but 
also in various other sensory, sympathetic and parasympathetic ganglia as well as in ab-
dominal lymphoid tissue.  
The present study in this dissertation follows up by aiming to answer remaining questions 
e.g. regarding the likely transportation route toward alternative latency locations and the 
predominant cell tropism during latency at these sites of persistence. Therefore, we com-
pared EHV-1 viral load and distribution on 70 dpi to a time point closer to acute infection 
(30 dpi) and hypothesized that EHV-1 chronic persistent infection is influenced by the time 
passed after inoculation. Furthermore, we aimed to investigate the cellular localization of 
latent EHV-1 as this information is crucial for elucidating the molecular basis of EHV-1 
latency.  
Overall, reflecting upon the review of recent literature in the field of EHV-1 (and related 
herpesvirus) latency, the main study in this dissertation provides novel insights into EHV-1 
latency pathogenesis.  
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II. LITERATURE REVIEW 
1. Molecular biology of EHV-1 
1.1. Taxonomy 
The International Committee on Taxonomy of Viruses (ICTV) classifies EHV-1 as a mem-
ber of the order Herpesvirales (DAVISON, 2010). Being identified in the past solely 
through their typical herpes virion architecture, novel nucleotide sequencing data allowed 
to further classify herpesviruses of mammals, birds and reptiles (the Herpesviridae), fish 
and amphibians (the Alloherpesviridae) and bivalves (the Malacoherpesviridae) 
(DAVISON et al., 2009). This assigns EHV-1 to the family of Herpesviridae, among which 
it shares certain biological properties with other family members. However, differences in 
host range, cell tropism and replication cycle subdivide the Herpesviridae in subfamilies 
of (A) Alpha-, (B) Beta- and (C) Gammaherpesvirinae ((DAVISON et al., 2009; PELLETT 
& ROIZMAN, 2013).  
A variable host range, relatively short reproductive cycle, rapid cell spread, and efficient 
destruction of infected cells characterizes EHV-1 as a member of the Alphaherpesvirinae. 
Notably, while latency is a hallmark of all herpesviruses, the subfamilies differ in their cell 
tropism for latency establishment (ROIZMAN & BAINES, 1991; PELLETT & 
ROIZMAN, 2013). For example, while Alphaherpesviruses are generally thought to re-
main latent particularly in peripheral sensory nerves, Gammaherpesviruses choose lym-
phoid tissue as harbor during latency (PELLETT & ROIZMAN, 2013).  
Important other members of the Alphaherpesvirinae include pathogens infecting humans 
(HSV-1, HSV-2, and VZV), avian species (Gallid Herpesvirus 1 (GaHV-1, Infectious lar-
yngotracheitis virus), GaHV-2, Marek’s Disease Virus), as well as mammals (Suid Her-
pesvirus 1 (SuHV-1, Pseudorabies virus (PsRV)), BoHV-1 (Infectious bovine rhinotrache-
itis virus), BoHV-5 (Bovine encephalitis herpesvirus), Canid Herpesvirus 1 (CaHV-1), 
Felid Herpesvirus 1 (FeHV-1). Besides to EHV-1, equids are the natural hosts to the Al-
phaherpesviruses EHV-3 (Equine coital exanthema virus), EHV-4 (Equine rhinopneumon-
itis virus), EHV-6 (Asinine Herpesvirus 1), EHV-8 (Asinine Herpesvirus 3) and EHV-9 
(Gazelle Herpesvirus 1). Other known herpesviruses in equids include EHV-2, EHV-5, 
EHV-7 (Asinine Herpesvirus 2) and belong to the subfamily of Gammaherpesviruses 
(TELFORD et al., 1993; BORCHERS et al., 1999; MA et al., 2013). 
Based on genome structure, - size and protein similarity, EHV-1 belongs to the genus 
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Varicellovirus along with the important animal pathogens SuHV-1, BoHV-1, BoHV-5, 
CaHV-1, and FeHV-1 (DAVISON, 2010). Notably, the human pathogen VZV is the pro-
totype for Varicellovirus research and is often represented by its close relative Simian 
Varicella Zoster Virus (SVV) in natural host models (ZERBONI & ARVIN, 2016).  
1.2. Viral structure and genomic organization  
EHV-1 features the typical Alphaherpesvirinae virion structure: A single copy of double 
stranded (ds) DNA is surrounded by a protective icosahedral capsid, which comprises 
six proteins and is of approximately 100-110 nanometers in diameter (PERDUE et al., 
1975; PELLETT & ROIZMAN, 2013). This nucleocapsid is encompassed by 12 proteins 
forming an interlayer, called tegument (MCLAUCHLAN & RIXON, 1992), and finally by 
an envelope derived from host cellular membranes. The envelope consists of lipids, poly-
amines, and a total of 12 viral glycoproteins which are projecting from the surface: Eleven 
glycoproteins have functional homologues present in HSV-1 (gB, gC, gD, gE, gG, gH, gI, 
gK, gL, gM, gN) and one glycoprotein (gp2) is unique for EHV-1 and its close relative 
EHV-4 (TURTINEN & ALLEN, 1982; PAILLOT et al., 2008). 
The genome of EHV-1 was the third Alphaherpesvirus genome to be sequenced, following 
those of VZV and HSV-1 (TELFORD et al., 1992). It is 150,223 basepairs (bp) in length 
with a G + C base content of 56,7 %. At least 78 distinct genes are organized collinearly 
with those of their human Alphaherpesvirus counterparts within the following components: 
two unique segments (unique long (UL) and unique short (US)) that are flanked by two 
repeat regions (internal repeat (IR) and terminal repeat (TR)) (TELFORD et al., 1992; 
SHAKYA et al., 2017). While originally four identical Open Reading Frames (ORFs) were 
found to be copied in the IR/TR region (ORF 64, 65, 66, 67) (TELFORD et al., 1992), this 
number was updated by the characterization of two additional genes of regulatory function 
(ORF 77, 78) (HOLDEN et al., 1992; KIM et al., 2006; AHN et al., 2007). ORF 1- 63 are 
located in UL and ORF 68-76 in US (TELFORD et al., 1992). 
While the most important encoded proteins associated with the virion, viral replication 
functions and gene regulation have been discovered so far (TELFORD et al., 1992; 
SLATER, 2014), the entire coding potential of the EHV-1 genome has yet to be elucidated. 
We can therefore expect to gain exciting new insights by novel Next Generation Sequenc-
ing techniques (e.g. total RNA Sequencing, microRNA Sequencing, target enriched RNA 
Sequencing) in the future.  
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1.3. Cell infection cycle 
EHV-1 can infect a variety of cell types, ranging from respiratory tract epithelial cells dur-
ing initial infection to mononuclear cells during viremia and to vascular endothelial cells 
of the central nervous system or the uterus (OSTERRIEDER & VAN DE WALLE, 2010). 
During the productive (acute) infection, the virus enters these target cells, replicates and 
propagates to high numbers of new virion particles. This infection cycle results in lysis of 
the infected cell and is therefore named lytic infection cycle (SLATER, 2014). Inde-
pendently, all herpesviruses can also enter a latent cycle in certain cell types, resulting in a 
non-productive chronic persistent infection. The cell tropism for latency establishment is 
more restricted than for lytic infection and is specific for each herpesvirus subfamily 
(PENKERT & KALEJTA, 2011). Like all Alphaherpesviruses, EHV-1 typically estab-
lishes latency in sensory neurons of the trigeminal ganglia (TG) (SLATER et al., 1994; 
EFSTATHIOU & PRESTON, 2005; BLOOM, 2016). However, EHV-1 also seems to be-
have lymphotropic for its latency establishment as latent EHV-1 has been detected previ-
ously in respiratory tract-associated lymphoid tissue (RALT) and in circulating CD8+ 
T-lymphocytes (T-cells) (WELCH et al., 1992; EDINGTON et al., 1994; CHESTERS et 
al., 1997; SMITH et al., 1998). The entry into either infection cycle is orchestrated upon 
entry into the host cell by a still unknown control mechanism (SLATER, 2014).  
Regardless of the target cell and the two different outcomes of the biphasic cycle, each 
infection starts with the coordinated process of viral entry (AZAB & OSTERRIEDER, 
2017): Following direct contact with EHV-1 or contact with infected cells, viral envelope 
glycoproteins (mainly gC and gB) bind to cell surface heparan sulfate proteoglycan 
(HSPG) and chondroitin sulfate proteoglycans (CSPG) (OSTERRIEDER, 1999; AZAB & 
OSTERRIEDER, 2017). Once attached, the virus is transported along filopodia (a mecha-
nism also referred to as “surfing”) towards the cell body, where gD associates with specific 
entry receptors (AZAB & OSTERRIEDER, 2017). Equine major histocompatibility com-
plex I (MHC-I) serves as an entry receptor on fibroblasts, epithelial and endothelial cells 
(KURTZ et al., 2010; SASAKI et al., 2011). There is also evidence of a yet undiscovered 
unique entry receptor for EHV-1 which is involved in gD binding (FRAMPTON et al., 
2005). Subsequently, the actual entry is performed either by fusion of the viral envelope 
with the host cell membrane or through endocytosis depending on the cell type 
(FRAMPTON et al., 2007; VAN DE WALLE et al., 2008; HASEBE et al., 2009) and the 
nucleocapsid and tegument proteins are released into the cell. While most of the tegument 
proteins separate from the capsid during this process, a few inner tegument proteins remain 
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bound and connect with dynein motor proteins linked to cell microtubules (FRAMPTON 
et al., 2010). This forms a transport complex along microtubules, which enables the viral 
capsid to be actively transported towards the nucleus. After docking to the nuclear pore 
complex (NPC), the capsid releases the viral genome into the nucleus while itself remains 
behind in the cytoplasm (OJALA et al., 2000; PAILLOT et al., 2008). The subsequent 
steps, taking place in the nucleus, are characterized by viral gene transcription and its reg-
ulation, which differs fundamentally depending on whether the virus enters a lytic or latent 
cycle (JONES, 2013; SLATER, 2014).  
1.3.1. Viral gene expression during productive and latent infection  
The lytic cycle is defined by viral DNA replication, protein expression and assembly of 
new virion particles. Once the viral DNA is released to the nucleus, the viral gene expres-
sion is activated, the core of which is a tightly regulated cascade of immediate early (IE), 
early (E) and late (L) genes (CAUGHMAN et al., 1985; GRAY et al., 1987b; SMITH et 
al., 1992). Viral regulatory gene products and host cell proteins orchestrate up- and down-
regulation of the distinct phases of viral gene expression (see chapter 1.3.2). The first gene 
to be transcribed is the sole IE gene (ORF64), which is required for E and L gene expres-
sion. Early gene expression initiates viral DNA replication (GRAY et al., 1987b; GRAY 
et al., 1987a; SMITH et al., 1992) and L genes are eventually transcribed, encoding for 
mainly viral structural proteins, required for virion assembly. Once the cycle is complete, 
newly generated viral DNA is packed into capsids. Nucleocapsids then associate with some 
tegument proteins and leave the nucleus through the inner and outer nuclear membrane. 
Further tegument proteins are added in the cytoplasm and the virus acquires its final enve-
lope, containing all viral glycoproteins by fusing with a vesicle originated from the Golgi 
complex. Finally, a new generation of infectious virions egresses from the cell which in-
evitably results in death of the latter (PAILLOT et al., 2008; CARTER & SAUNDERS, 
2013).  
During the latent cycle of infection, the entire round of transcription and translation of the 
gene cascade is not accomplished - precisely, lytic gene expression is repressed 
(PENKERT & KALEJTA, 2011). The cycle begins with establishment of latency, where 
the viral gene transcription cascade is rapidly silenced and gene expression limited to la-
tency-associated transcripts (LATs) (see chapter 3). The virus enters a dormant state, is 
non-infectious and persists as a circular episome (EFSTATHIOU et al., 1986; 
MELLERICK & FRASER, 1987; EFSTATHIOU & PRESTON, 2005). This process is 
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initiated by a combination of viral and host factors, which build the basis of a careful bal-
ance during maintenance of latency (see chapter 3). Importantly, the silencing of viral 
genes during latency is not ultimate and whereas some late genes (strict-late) are strictly 
inhibited, the expression of some other late genes (leaky-late) still occurs on a low-level 
basis (NICOLL et al., 2012; ROIZMAN et al., 2013). Periodically, external stimuli (e.g. 
stress and immunosuppression) animate viral gene expression, which can result subse-
quently in re-entering the lytic cycle (reactivation event) (PENKERT & KALEJTA, 2011; 
JONES, 2013).  
1.3.2. Gene transcription cascade 
The gene regulation cascade is crucial for understanding the characteristics of a lytic and 
latent life cycle, their balance, as well as their diagnosis approach. The key role in the 
complex series plays an array of regulatory genes and their proteins (P): one IE gene 
(ORF64, IEP), four E genes (ORF65, EICP22; ORF5, EICP27; ORF63, EICP0; IR2, IRP) 
and one L gene (ORF12, ETIF). 
The cascade is initiated by the ETIF Protein (HSV-1 VP16 homologue), a tegument pro-
tein, which is transported into the infected cell and activates IE gene expression 
(PUREWAL et al., 1994; LEWIS et al., 1997). The IE gene, represented twice in the in-
verted regions of the EHV-1 genome, has been shown to be essential for viral replication 
in vitro (GRUNDY et al., 1989; GARKO-BUCZYNSKI et al., 1998). The encoded IE pro-
tein is synthesized subsequently by host cell RNA polymerase and embodies the key regu-
latory factor (GRAY et al., 1987b; GRAY et al., 1987a). As such, it features autoregulation 
of its own expression, activation of other viral promoters and acts in cooperation with 
EICP22 and EICP27 proteins to initiate E and L gene expression (SMITH et al., 1992; 
ZHAO et al., 1992; HOLDEN et al., 1995). Within the IE gene maps the IR2 gene, which 
is expressed during E and L stages and seems to have a downregulating function for the 
IE promoter (HARTY & O'CALLAGHAN, 1991; SMITH et al., 1994). Transcription of 
E genes and subsequent E protein synthesis induces viral DNA replication (MUYLAERT 
et al., 2011). While EICP22 and EICP27 proteins act in concert with IE protein, EICP0 pro-
tein can activate all classes of EHV-1 promoters independently and seems to be particularly 
important for L gene activation (BOWLES et al., 1997; BOWLES et al., 2000). Once viral 
replication has started, L genes are expressed at maximum levels (PELLETT & 
ROIZMAN, 2013). They encode structural proteins forming the virion, the assembly of 
which marks the end of a lytic cycle.  
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1.3.3. Diagnosis of viral infection state in the present study 
One part of the present study focuses on the differentiation of EHV-1 lytic or latent infec-
tions in tissue samples. Basis for this diagnosis is the presence or absence of L gene mRNA 
and virion proteins as those gene products indicate a complete productive round of repli-
cation – hence they define a lytic cycle. Therefore, a sample can be defined as latently 
infected when viral genomic DNA is present (via qPCR) while L mRNA and L protein is 
not detectable (PUSTERLA et al., 2010). More specifically, the transmembrane gB 
mRNA, encoded by L gene ORF33 and gB, is generally used as indicator for lytic infection 
using reverse transcription qPCR (RT qPCR) and Immunohistochemistry (IHC) respec-
tively (PUSTERLA et al., 2010). The transmembrane protein gB is highly conserved 
among all herpesviruses (MCGEOCH & COOK, 1994), is essential for viral growth in 
vitro and functions in target cell attachment, penetration, and cell-to-cell fusion 
(WELLINGTON et al., 1996; NEUBAUER et al., 1997; SPIESSCHAERT et al., 2015).  
Notably, there is a caveat concerning this definition: While it is generally accepted that 
infectious virus cannot be detected during latency (JONES, 2003), viral gene expression is 
frequently animated during latency without resulting in re-entering the lytic cycle. Thus, 
there is the possibility that low abundance of gB mRNA might be present during latency 
as the gB gene is a leaky-late gene (ROIZMAN et al., 2013). Overall, although low levels 
of gB mRNA might be expressed occasionally during latency, it is unlikely that they reach 
high enough levels to be detected by the RT qPCR approach unless there is lytic gene 
expression including viral replication and virion assembly.  
2. EHV-1 Transmission and Pathogenesis  
2.1. Transmission, pathogenesis and disease manifestation 
EHV-1 is a ubiquitous viral pathogen and causes respiratory disease, abortion, and neuro-
logic disease (equine herpesvirus myeloencephalopathy (EHM)) in horses worldwide. 
Horses usually get exposed to EHV-1 and to its close relative EHV-4 very early in life, 
probably as young foals while having contact with their nursing dam (GILKERSON et al., 
1999b; GILKERSON et al., 1999a). Interestingly, whilst EHV-4 is genetically strikingly 
similar to EHV-1, infections with EHV-4 usually manifest only in mild respiratory disease 
but abortion and neuropathogenicity is scarce (PATEL & HELDENS, 2005). Following 
primary infection, both viruses establish latency in a high percentage of horses, the latter 
of which then become an important virus reservoir. Devastating EHV-1 disease outbreaks 
often start with a single horse (carrier animal), where latent EHV-1 reactivates following 
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stress events (transport, hospitalization, change in horse population) or due to an immuno-
compromised state. Subsequent transition to lytic infection leads to rapid transmission to 
susceptible herd mates and potentially to disease manifestation.  
Transmission of EHV-1 typically occurs through inhalation/ingestion of virus or direct 
contact with infectious materials (LUNN et al., 2009). Subsequently, EHV-1 targets epi-
thelial cells of the URT mucosa, where entering the lytic infection cycle results rapidly in 
primary replication followed by epithelial cell destruction and nasal viral shedding (KYDD 
et al., 1994a). In young or immunological naïve horses, respiratory symptoms like nasal 
and/or ocular discharge, occasional coughing and primary fever predominate, whereas res-
piratory disease is rather mild or subclinical in the adult horse (PAILLOT et al., 2008; 
WILSTERMAN et al., 2011; GIESSLER et al., 2020b). Furthermore, simultaneously to 
the active replication in the URT, EHV-1 infects adjacent sensory nerve endings and is 
transported to the TG, where it establishes life-long latency by manipulating the host cell 
environment and is creating a balance with the immune system (see chapter 3.3). Further-
more, EHV-1 features several additional immunomodulatory properties: During the initial 
phase of replication, EHV-1 is able to increase its virulence by modulating the innate im-
mune response at the respiratory epithelium; for example by interfering with chemotaxis 
of leukocytes and/or expression of interferons (SOBOLL HUSSEY et al., 2011; SOBOLL 
HUSSEY et al., 2014). Another important strategy of EHV-1 that aims to evade the elimi-
nation through the immune system involves invading the latter by targeting and hiding in 
immune cells (POELAERT et al., 2019). Specifically, EHV-1 infects and uses monocytes 
in the URT to be transported through the connective tissue to vascular endothelium and 
respiratory tract-associated lymphoid tissue (RALT) (KYDD et al., 1994b; GRYSPEERDT 
et al., 2010; VANDEKERCKHOVE et al., 2010; BAGHI & NAUWYNCK, 2014), which 
is also a known latency site for EHV-1 (CHESTERS et al., 1997). The virus is then trans-
ferred to PBMCs and subsequently distributed throughout the body in a cell-associated 
viremia, which can be typically detected until around day 14 post infection (GIBSON et 
al., 1992; HUSSEY et al., 2006; ALLEN, 2008; LUNN et al., 2009; PUSTERLA et al., 
2009; GOEHRING et al., 2010b) and a secondary fever usually peaks during this period 
(HUSSEY et al., 2006; GOEHRING et al., 2010a; GOEHRING et al., 2010b). Viremia is 
therefore essential for reaching the vascular endothelium of secondary infection sites such 
as CNS, uterus, gonads or the eye (DUTTA & MYRUP, 1983; EDINGTON et al., 1986; 
KYDD et al., 1994b; TEARLE et al., 1996; ALLEN & BREATHNACH, 2006; WALTER 
et al., 2012; HUSSEY et al., 2013), where endothelial cell infection of arterioles may cause 
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vasculitis and thrombosis (EDINGTON et al., 1986; GOEHRING & VAN 
OLDRUITENBORGH-OOSTERBAAN, 2001; PUSTERLA & HUSSEY, 2014). In spinal 
cord and brain, the adjacent affected neural tissue becomes necrotic following hypoxia and 
ischaemia, referred to as “equine stroke” (EDINGTON et al., 1986), which can cause mye-
loencephalopathy (EHM). Furthermore, there is growing evidence that activation of the 
coagulation cascade is linked to EHV-1 viremia and thus may be a contributing factor in-
volved in thrombosis formation (GOEHRING et al., 2013; YEO et al., 2013; STOKOL et 
al., 2015; WILSON et al., 2019). Similarly, arteriolar thrombosis in the endometrium of 
the pregnant uterus causes late term abortion (GOEHRING & VAN 
OLDRUITENBORGH-OOSTERBAAN, 2001; SMITH & BORCHERS, 2001; 
GARDINER et al., 2012) with neonatal foal death being a consequence of intrauterine 
EHV-1 infection (GOEHRING & VAN OLDRUITENBORGH-OOSTERBAAN, 2001). 
Infections with EHV-4 on the other hand, typically do not cause neurologic disease or 
abortion like EHV-1, albeit their close relatedness and similarity in initial infection and 
replication in the URT. Although the differences in pathogenesis is not completely under-
stood, it has been shown that EHV-4 usually does not cause cell-associated viremia (MA 
et al., 2013).  
Therefore, it seems likely that viremia represents a key element in EHV-1 infections and 
is prerequisite for secondary EHV-1 disease manifestations (ALLEN, 2008; GOEHRING 
et al., 2010b; OSTERRIEDER & VAN DE WALLE, 2010). However, neurologic disease 
is usually developed only in a small percentage of EHV-1 infected and viremic horses and 
viral and host factors contributing to EHM pathogenesis are still poorly understood 
(GOEHRING et al., 2006; LUNN et al., 2009; HOLZ et al., 2017). It has been shown that 
EHV-1 neuropathogenicity is strongly associated with the virulence of naturally occurring 
DNA polymerase gene (ORF30) strain variants: Specifically, a nucleotide polymorphism 
resulting in a single amino acid variation of the polymerase (asparagine (N) changes to 
aspartic acid (D) at amino acid position 752) increases the neuropathogenic capacity 
(NUGENT et al., 2006). It has been shown in infection experiments, that neuropathogenic 
D752 strains are associated with higher levels and a prolonged period of viremia than their 
non-neuropathogenic counterparts (N752 strains); the higher load of circulating virus and 
the prolonged exposure of the vascular endothelium supposedly increases the risk for EHM 
development (GOODMAN et al., 2007; ALLEN, 2008; LUNN et al., 2009; HOLZ et al., 
2017).  
This theory is also supported by the dramatic increase of EHM incidence in old horses 
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(> 20 years of age), as a likewise significantly higher viral load is detectable during viremia 
in the elderly compared to younger individuals (HENNINGER et al., 2007; ALLEN, 2008; 
GIESSLER et al., 2020b). Age-related changes in the immune response most likely drive 
the severity of EHV-1 pathogenesis (HENNINGER et al., 2007), however, host factors 
contributing to EHM development are largely unknown and currently under investigation 
by our research group. 
2.2. Peripheral blood mononuclear cell tropism during viremia 
EHV-1 is capable to infect monocytes, T- an B-lymphocytes in vitro and in vivo, but the 
main subpopulation within PBMCs that EHV-1 targets during primary infection has been 
controversially discussed in literature (VAN DER MEULEN et al., 2000; GOODMAN et 
al., 2007; GRYSPEERDT et al., 2010; WILSTERMAN et al., 2011; POELAERT et al., 
2019). It has been shown in nasal mucosal explant studies that EHV-1 efficiently ‘hi-jacks’ 
monocytes for the initial transport upon replication in the respiratory mucosa 
(VANDEKERCKHOVE et al., 2010), which was also reported in vivo (GRYSPEERDT et 
al., 2010). Furthermore, T-lymphocytes (T-cells) seem to be important carrier cells during 
viremia (WILSTERMAN et al., 2011; POELAERT et al., 2019). However, whether EHV-1 
is more prone to infect CD4+- or CD8+ T-cells remains inconclusive (SLATER et al., 
1994; CHESTERS et al., 1997; HENNINGER et al., 2007; WILSTERMAN et al., 2011; 
POELAERT et al., 2019). Another important point of discussion concerns the state of the 
virus within mononuclear cells during viremia, which has yet to be defined. There is evi-
dence that EHV-1 gene expression is silenced in monocytes, including reduced expression 
of viral proteins (VAN DER MEULEN et al., 2000; LAVAL et al., 2015). This strategy 
may provide an essential advantage for the virus to hide within PBMCs during the period 
of viremia. Interestingly, Poelaert et al. (2019) showed that EHV-1 is able to efficiently 
replicate in T-cells, but opposed to what is known for lytic infections, virion assembly is 
not completed. Viral capsids are formed but retained in the nucleus of the infected cell until 
it binds to a secondary target cell, where the virus then can be transferred through the for-
mation of a virological synapse (POELAERT et al., 2019). This is important to further 
understand the transfer of the virus to the endothelium of the CNS and the pregnant uterus 
and hence for EHV-1 pathogenesis. Interestingly, the same phenomenon of nuclear accu-
mulation of viral capsids and cell-to cell fusion has also been described in neurons and non-
neuronal cells infected with VZV, the very closely related human Varicellovirus 
(REICHELT et al., 2008; REICHELT et al., 2011). It is tempting to assume that this strat-
egy may also be used by EHV-1 to infect neurons potentially during latency establishment. 
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3. Aspects of latency 
3.1. Latency sites of relevant Alphaherpesviruses 
Alphaherpesviruses establish latency predominantly in neurons of sensory ganglia 
(SLATER et al., 1994; JONES, 2003; BLOOM, 2016; DEPLEDGE et al., 2018). Typi-
cally, trigeminal ganglia (TG) represent preferred sites for latency establishment as their 
sensory nerve endings are readily accessible for newly synthesized virions during produc-
tive (primary) infection in the respiratory epithelium (BARINGER & SWOVELAND, 
1973; MEIER et al., 1993; SLATER et al., 1994; BAXI et al., 1995; RAMAKRISHNAN 
et al., 1996; JIANG et al., 1998). However, latency pathogenesis and latency locations of 
different Alphaherpesviruses coevolved with their natural hosts and often mirror the spe-
cific pathogenesis of the initial infection (MAHALINGAM et al., 1992). Below there is a 
brief review on latency pathogenesis and locations of different EHV-1 relatives. Within the 
subfamily of Alphaherpesviruses, HSV-1 belongs to the genus Simplexvirus, VZV and 
BoHV-1 both belong like EHV-1 to the genus Varicellovirus. 
3.1.1. Herpes Simplex Virus 1 
HSV-1 is characterized by a very high seroprevalence in the human population and infec-
tions typically occur early in life by oral transmission (BLOOM & DHUMMAKUPT, 
2016). Primary infection is generally subclinical and allows the virus to establish a persis-
tent infection mainly in TG for the life of the host (see chapter 3.2). Periodically, mostly 
stress-induced reactivation may cause either asymptomatic shedding or a localized ulcer-
ated lesion (cold sores, herpes labialis) on a distinct area of the lip, which is innervated 
from the infected neuron (BLOOM & DHUMMAKUPT, 2016). A recent review revealed 
that asymptomatic shedding occurs in at least 70 % of the population at least once a month 
(MILLER & DANAHER, 2008), which indicates frequent low-level reactivation and re-
flects the high seroprevalence of HSV-1.  
Consistent with HSV-1 infections being predominantly localized to the oropharyngeal re-
gion, HSV-1 latency is usually established mainly in TG and spinal cord dorsal root ganglia 
(DRG) (BARINGER & SWOVELAND, 1973; MAHALINGAM et al., 1992; OBARA et 
al., 1997) but also in other sensory (pterygopalatine, ciliary, otic, submandibular, genicu-
late) and autonomic (superior cervical and nodose) ganglia of the head and neck 
(RICHTER et al., 2009). For example, viral transmission to the eye can result in local rep-
lication and subsequent latency establishment in ganglia pteryopallatine and superior cer-
vical ganglia (RICHTER et al., 2009; BLOOM & DHUMMAKUPT, 2016). In severe cases 
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of primary ocular infections and reactivation, HSV-1 causes recurrent corneal lesions, 
which can often result in blindness of the individual (LIESEGANG, 2001). Further studies 
discussed the involvement of HSV-1 in esophageal and gastroduodenal lesions following 
ingestion of HSV-1 during primary infection and suggested subsequent latency establish-
ment in nodose ganglia as part of the vagus nerve (WARREN et al., 1978; LÖHR et al., 
1990; GESSER & KOO, 1997; NAGEL et al., 2014). Furthermore, there is evidence of 
latent infection of thoracic sympathetic trunk ganglia, however only in rare cases 
(GALLOWAY et al., 1979; MAHALINGAM et al., 1992; NAGEL et al., 2014). 
While overall not common for HSV-1, infections may result in cell-associated viremia in 
rare cases of immunocompromised patients or neonates (SMITH, 2012). During this se-
vere, disseminated HSV-1 disease, the virus is distributed to various organs (liver, spleen, 
lung, lymph nodes), and results often in fatal encephalitis (WHITLEY et al., 1982; LUKER 
et al., 2003; BLOOM & DHUMMAKUPT, 2016). The travel route towards the brain may 
be via blood during disseminated disease and/or by neuronal transport from infected gan-
glia (WHITLEY et al., 1982; KENNEDY & CHAUDHURI, 2002). As latent HSV-1 can 
be detected frequently in normal brain tissue without history of severe HSV-1 disease, 
hence without history of HSV-1 viremia, neuronal HSV-1 transfer towards CNS seems to 
occur on a regular basis (GORDON et al., 1996; KENNEDY & CHAUDHURI, 2002).  
Taken together, HSV-1 latency seems to be generally limited to cranial nerve ganglia, 
which are accessible during primary infection of the oropharynx.  
3.1.2. Varicella Zoster Virus 
The human Alphaherpesvirus VZV causes varicella (chickenpox) during primary infection, 
which is a generalized vesicular skin rash. Unlike HSV-1, VZV is transported via cell-
associated viremia throughout the body resulting in widespread infection of the skin. Sub-
sequently, latency is established in sensory and sympathetic neurons, where it can be reac-
tivated to cause a second, more localized form of disease, herpes zoster (shingles) 
(DEPLEDGE et al., 2018). This is characterized by a vesicular rash which is localized to 
the specific skin area innervated by the respective infected latency site. The main sites of 
VZV latency are thought to be sensory neurons of TG (GILDEN et al., 1983; KENNEDY 
et al., 1998; LEVIN et al., 2003) and DRG (KENNEDY et al., 1999; REICHELT et al., 
2008) where VZV gains access to the neurons in proximity of infected skin lesions during 
primary infection (chickenpox) (FURUTA et al., 1997). However, various other sensory 
ganglia (geniculate, vestibular, spiral) and autonomic (thoracic sympathetic trunk ganglia, 
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nodose, enteric) ganglia may be potential additional latency sites in which VZV DNA has 
been readily detected (GILDEN et al., 1987; FURUTA et al., 1992; MAHALINGAM et 
al., 1992; FURUTA et al., 1997; GILDEN et al., 2001; CHEN et al., 2011; DEPLEDGE et 
al., 2018). Interestingly, potential latency sites like vestibular and spiral ganglia are not 
directly linked by neurons to the epidermis of the skin (FURUTA et al., 1997), and there-
fore not easily accessible via viral neuronal transport. Furthermore, VZV DNA can be de-
tected in sensory ganglia before the primary vesicular skin infection occurs (ZERBONI et 
al., 2005; OUWENDIJK et al., 2013). Therefore, there is growing evidence that cell-asso-
ciated viremia serves as an alternative, hematogenous route towards VZV latency sites 
(ZERBONI et al., 2005; OUWENDIJK et al., 2013). Indeed, besides its characteristic neu-
rotropism, VZV is also known to be lymphotropic (KU et al., 2002; SCHAAP et al., 2005). 
It has been shown that T-cells, which transport the virus to skin regions during viremia, 
also transferred VZV into DRG in a xenograft mouse model (ZERBONI et al., 2005). How-
ever, studying VZV latency pathogenesis is challenging due to its immense human-cell 
tropism and a lack of effective animal models (BLOOM, 2016). Detailed studies to identify 
the pathogenesis of Simian Varicella Virus (SVV, a close relative to VZV) were conducted 
by Ouwendijk et al. (2013 and 2016) in the natural host (African green monkeys). The 
authors showed that SVV infects T-cells during primary infection, which transport the virus 
throughout the body during viremia. Infected T-cells could then be identified adjacent to 
neurons up to 20 dpi. This supports the results of VZV in in vitro studies (GRIGORYAN 
et al., 2015) and xenograft in vivo mouse models (ZERBONI et al., 2005) and suggests that 
VZV lymphotropism and subsequent hematogenous spreading enhances the frequency of 
latency establishment in various neurons (ZERBONI & ARVIN, 2016). 
3.1.3. Bovine Herpesvirus 1 
BoHV-1 is an important pathogen of cattle causing infectious bovine rhinotracheitis (IBR), 
genital disorders (infectious pustular vulvovaginitis, balanopostitis), abortions, fatal sys-
temic infections in calves and in rare cases meningoencephalitis (BRYAN et al., 1994; 
ROELS et al., 2000; JONES, 2016). Depending on whether initial infection occurs on up-
per respiratory tract or genital tract mucosa, latency is established via neuronal transport in 
sensory neurons of TG or sacral ganglia, respectively (JONES, 2016). Additional neural 
latency sites may exist but have not been further investigated so far (JONES, 2016). Im-
portantly, BoHV-1 suppresses the immune system during primary infection: By targeting 
and destroying CD4+ T-cells and impairing cell-mediated immunity, BoHV-1 facilitates 
manifestation of secondary bacterial infections that may result in live-threatening 
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bronchopneumonia, also referred to as bovine respiratory disease complex (shipping fever) 
(ESKRA & SPLITTER, 1997; WINKLER et al., 1999; JONES & CHOWDHURY, 2008). 
Lymphotropism also enables BoHV-1 to be distributed to secondary infection sites in a 
cell-associated viremia, and BoHV-1 was detected in PBMCs and lymphoid tissue (tonsils, 
lymphnodes, spleen) during acute infection (BAGUST & CLARK, 1972; NYAGA & 
MCKERCHER, 1979; CASTRUCCI et al., 1992; BRYAN et al., 1994; KAASHOEK et 
al., 1996; FUCHS et al., 1999; WINKLER et al., 1999). However, some authors indicate 
that viremia seems to occur mainly in very young calves resulting in systemic infection 
(KAASHOEK et al., 1996; MWEENE et al., 1997). Consistent with its lymphotropism, 
BoHV-1 can persist in lymphocytes after acute infection (FUCHS et al., 1999) and estab-
lishes latency in non-neural sites like PBMCs (FUCHS et al., 1999; WANG et al., 2001), 
tonsils (WINKLER et al., 2000), lymphnodes, and spleen (MWEENE et al., 1997).  
A great advantage of BoHV-1 latency research is the fact that it can be studied in calves as 
the natural host. In addition, latent BoHV-1 can be reliably reactivated by treating latently 
infected calves with the synthetic corticosteroid dexamethasone. This model therefore pro-
vides valuable research possibilities to further investigate the switch from latency to reac-
tivation (JONES, 2016). 
3.2. Latency establishment and reactivation in neurons 
With the onset of viral replication in the respiratory epithelium and infection of mononu-
clear cells, viral particles also start to enter axonal nerve endings by fusion with the neu-
ronal plasma membrane (JONES, 2013; SLATER, 2014; BLOOM, 2016). The subsequent 
active transport to the nucleus along microtubules is critical in neuronal cell infection con-
sidering the long distance between axonal nerve ending and neuronal nucleus located in 
ganglia (DIEFENBACH et al., 2008). Furthermore, the consistent polar orientation of mi-
crotubules in axons requires an efficient retrograde transport from plus end (axon termini) 
to minus end (nucleus) (SMITH, 2012). At least three inner tegument proteins have been 
described to build a retrograde transport complex with dynein motor proteins on microtu-
bules for efficient capsid delivery to the neuronal nucleus (LUXTON et al., 2005; 
ANTINONE & SMITH, 2010; SMITH, 2012; RICHARDS et al., 2017). The importance 
of a well-functioning transport complex for latency establishment in neurons has been re-
cently highlighted by HSV-1 and PsRV studies, where mutated versions of a specific com-
plex protein (pUL37) led to abort of capsid delivery to the nucleus and therefore inhibit 
latency establishment in vitro and in vivo (RICHARDS et al., 2017; PICKARD et al., 
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2020). Upon arrival to the neuronal cell body, viral genome is then released into the nucleus 
and circularizes. Subsequently, latency is established either promptly or following a short 
replication cycle (COEN et al., 1989; EFSTATHIOU et al., 1989; KATZ et al., 1990; 
STEINER et al., 1990). While replication is not necessary for latency establishment, effi-
cient replication and subsequent spreading can result downstream in higher numbers of 
latently infected neurons (THOMPSON & SAWTELL, 2000). The axonal architecture of 
neurons possibly favors prompt latency establishment as the virus has to overcome long 
travel distances: It is discussed for HSV-1 that sufficient amounts of the viral gene cascade 
transactivator, VP16 (ETIF homologue), may not arrive at the distant neuronal nucleus 
resulting in a failure of initiating replication and therefore promoting immediate latency 
establishment (EFSTATHIOU & PRESTON, 2005; ANTINONE & SMITH, 2010; 
HAFEZI et al., 2012; SMITH, 2012)  
Notably, while latently infected neurons are present from day one post infection (BLOOM, 
2016), the term latency generally reflects the stable dormant viral state in the whole organ-
ism after the acute infection declines 14 – 21 dpi (GIBSON et al., 1992; HUSSEY et al., 
2006; ALLEN, 2008; LUNN et al., 2009; PUSTERLA et al., 2009; GOEHRING et al., 
2010b) and therefore is agreed to begin around 28 dpi (BLOOM, 2016).  
The latent state in its complexity of involved molecular and cellular mechanisms is still 
poorly understood (PENKERT & KALEJTA, 2011; ZERBONI & ARVIN, 2016). It is 
assumed that after abort of the viral gene transcription cascade, the viral genome associates 
tightly with cellular histones (DESHMANE & FRASER, 1989; KNIPE & CLIFFE, 2008) 
and persists in a quiescent form as a circular episome (EFSTATHIOU et al., 1986; 
MELLERICK & FRASER, 1987). A precisely regulated balance between viral factors, 
neuronal environment and host immunity is now established (EGAN et al., 2013) 
(see chapter 3.3).  
Periodically, this balance is challenged by certain stimuli like stress, fever, tissue damage, 
or immune suppression (NICOLL et al., 2012). This can initiate unregulated transcription 
of multiple viral genes, an event which is referred to as animation (PENKERT & 
KALEJTA, 2011) and can ultimately result in reactivation (PENKERT & KALEJTA, 
2011; KENNEDY et al., 2015). However, animation including low-level lytic gene expres-
sion probably occurs frequently without culminating in virion assembly, but instead the 
virus re-enters the dormant state (PENKERT & KALEJTA, 2011; KIM et al., 2012; 
KENNEDY et al., 2015). There is still a lack of knowledge which criteria lead to the final 
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shift towards exit from latency, where animation is followed by organized IE, E, L gene 
transcription, viral DNA replication and virion assembly (KIM et al., 2012; KENNEDY et 
al., 2015). Upon reactivation, virions can egress directly from the neuronal cell body or 
travel anterogradely along axons towards the primary infection site (DIEFENBACH et al., 
2008; SMITH, 2012). Anterograde transport is likely promoted by kinesin molecules but 
overall not fully understood (SMITH, 2012): Whether viral particles (naked capsid and 
glycoproteins) are transported separately or as assembled enveloped virion in vesicles re-
mains inconclusive (DIEFENBACH et al., 2008; SMITH, 2012). Finally, the virus exits 
the axonal termini supposedly by exocytosis (SAKSENA et al., 2006), may then infect 
epithelial cells and either cause asymptomatic shedding or recurrent lesions. The axonal 
architecture of sensory neurons therefore allows the latent virus to retain a direct loophole 
to peripheral tissue sites and to new susceptible hosts eventually in case of reactivation.  
3.3. Maintenance of latency: balance between viral and host factors 
3.3.1. Host cell chromatin and gene regulation 
Upon release of the viral genome into the host cell nucleus, viral DNA is exposed to the 
nuclear environment (NICOLL et al., 2012). Unlike the bare viral DNA in virions, eukar-
yotic DNA is bound to histones and other proteins which pack up the long DNA molecule 
in a complex called chromatin (KNIPE & CLIFFE, 2008). Active and repressive forms of 
histones can regulate gene transcription, as they influence the density of chromatin upon 
genes. The activity state of histones as such is associated with amino acid tail modifica-
tions, most importantly acetylation and methylation (EFSTATHIOU & PRESTON, 2005; 
KNIPE & CLIFFE, 2008). For example, acetylation results in active chromatin and gene 
transcription. De-acetylation by histone de-acetylases (HDACs) therefore leads to chroma-
tin condensation and gene silencing. These host cell chromatin structures become associ-
ated with viral DNA (NICOLL et al., 2012; TALLMADGE et al., 2018). While this appears 
to be a host cell defense mechanism in order to silence viral gene expression via condensed 
chromatin, the virus itself is presumably actively involved in this process and may be able 
to manipulate the chromatin structure for its own gene regulation (WANG et al., 2005b; 
NICOLL et al., 2012; LAVAL et al., 2015). Indeed, during lytic HSV-1 infection, viral 
proteins like VP16 (ETIF homologue) and/or IE protein may reduce overall chromatin as-
sembly upon viral lytic genes and promote active (open) chromatin possibly by inhibiting 
HDACs (HOBBS & DELUCA, 1999; KENT et al., 2004; KNIPE & CLIFFE, 2008). For 
EHV-1, histone methylation (TALLMADGE et al., 2018) and acetylation (LAVAL et al., 
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2015) has been shown to regulate viral gene transcription during lytic infection.  
During latency, however, the viral episome is tightly associated with condensed forms of 
chromatin particularly upon viral lytic genes. It has been suggested for HSV-1 that this 
may be linked to the failure of VP16 delivery into the nucleus during latency establishment 
(KNIPE & CLIFFE, 2008; HAFEZI et al., 2012). While repressive chromatin is presuma-
bly involved in lytic gene silencing, acetylated (open) chromatin has been detected upon 
the sole gene region, which is active during latency: the LAT gene (NICOLL et al., 2012). 
In addition, LAT itself supposedly reduces active chromatin during latency (WANG et al., 
2005b; CLIFFE et al., 2009), implying one of the multiple potential mechanisms of LAT 
in its function as a latency regulator. 
3.3.2. The role of latency-associated transcripts  
Presumably all Alphaherpesviruses express LATs that contribute to the network of regula-
tion during latency (JONES, 2013; BLOOM, 2016; DEPLEDGE et al., 2018). However, 
their presence is overall not required for latency establishment (NICOLL et al., 2012). De-
spite years of research since their discovery in 1987 (SPIVACK & FRASER, 1987; 
STEVENS et al., 1987), the exact role and mechanism of action is still poorly understood 
(NICOLL et al., 2012) and best characterized in HSV-1 research. Supposedly, LATs are 
capable of reducing lytic gene expression (GARBER et al., 1997) by still unknown mech-
anisms. One possibility could be an anti-sense, inhibiting binding of LAT to IE mRNA 
(STEVENS et al., 1987), which aborts further translation processes. As already mentioned, 
another possible way could involve LAT dependent manipulation of host cell chromatin 
structure that associates with viral genes. For example, tightly condensed chromatin on 
viral lytic-gene promoters could be appreciated in the presence of LAT, but not in LAT 
negative mutants (WANG et al., 2005b). In addition, LATs may also be capable of sup-
porting neuronal survival through an anti-apoptotic mechanism (PERNG et al., 2000; 
INMAN et al., 2001; JONES, 2003; TORMANEN et al., 2019). Typically, LATs are en-
coded to a genomic region antisense to the IE gene (HSV-1 ICP0) and persist after splicing 
as a 2.0 kbp stable intron (JONES, 2003; EFSTATHIOU & PRESTON, 2005). While the 
LAT gene locus seems to be conserved among well-studied Alphaherpesviruses like 
HSV-1, VZV, and BoHV-1, the precise gene region encoding EHV-1 LAT is controver-
sially discussed in literature (HOLDEN et al., 1992; BAXI et al., 1995; CHESTERS et al., 
1997; BORCHERS, 1999; PUSTERLA et al., 2009; ABDELGAWAD et al., 2016; 
VARGAS-BERMUDEZ et al., 2018). During HSV-1 and BoHV-1 latency, LATs are 
II. Literature review 19 
abundantly expressed, which is why they are established markers used in HSV-1 and 
BoHV-1 latency diagnosis (JONES, 2003). Both HSV-1 and BoHV-1 LATs express micro-
RNAs (miRNAs) during latency (UMBACH et al., 2008; JABER et al., 2010; JURAK et 
al., 2010). Mi-RNAs are small (~22-nucleotide), non-coding RNAs, associated with viral 
gene regulation by targeting and binding to mRNAs (GREY, 2015). It has been shown that 
they may be able to suppress lytic gene transcription and support survival of latently in-
fected cells (NICOLL et al., 2012; GREY, 2015). BoHV-1 LAT additionally has coding 
potential for a protein with anti-apoptotic activity, which is a unique feature among known 
LATs of Alphaherpesviruses (JIANG et al., 1998; CIACCI-ZANELLA et al., 1999; MOTT 
et al., 2003; MEYER et al., 2007). Until recently, VZV was assumed to be the only Al-
phaherpesvirus not known to express LAT (BLOOM, 2016; ZERBONI & ARVIN, 2016). 
Depledge et al. (2018) revised this theory and succeeded in a breakthrough in VZV research 
by detecting a complex organized LAT using target enriched RNA Sequencing. Like 
HSV-1 and BoHV-1, the VZV LAT is encoded antisense to the corresponding VZV IE 
gene location but seems to be expressed at very low-levels and does not encode miRNA. 
Furthermore, the authors detected an additional IE transcript during VZV latency which is 
possibly involved in the process of reactivation (DEPLEDGE et al., 2018). Hence, the 
known functions of LATs, their size and level of transcription is not uniform among Al-
phaherpesviruses (EFSTATHIOU & PRESTON, 2005; DEPLEDGE et al., 2018).  
Several studies in the past detected transcripts during EHV-1 latency using in-situ hybrid-
ization (BAXI et al., 1995; CHESTERS et al., 1997), conventional nested PCR 
(CHESTERS et al., 1997; BORCHERS, 1999; ABDELGAWAD et al., 2016; VARGAS-
BERMUDEZ et al., 2018) or nothern blot analysis (HOLDEN et al., 1992). According to 
this data there is evidence that potential LATs are encoded to regions antisense to the ICP0 
homologue (ORF 63) (BAXI et al., 1995; BORCHERS, 1999; ABDELGAWAD et al., 
2016; VARGAS-BERMUDEZ et al., 2018) and/or antisense to a region overlapping the 
3’ end (CHESTERS et al., 1997) or 5’ end (HOLDEN et al., 1992) of the sole IE gene 
(ORF 64). But whether these are transcripts periodically expressed during low-level gene 
expression during latency or true LATs that are structurally and functionally comparable 
to those of HSV-1, BoHV-1 or VZV, remains to be elucidated. One can speculate that the 
putative EHV-1 LAT is not as abundantly expressed as in HSV-1 or BoHV-1 latency and 
similar to VZV LAT research, methods with higher sensitivity like RNA Sequencing are 
crucial to repeatedly define and characterize the molecular structure of EHV-1 LAT.  
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3.3.3. The role of different host cell types in ganglia  
3.3.3.1. Neuron-satellite glial cell complex 
Neurons are stable, long living cells that do not divide and normally express only low 
amounts of T-cell receptors (MHC class 1 and 2 molecules) (EGAN et al., 2013; SLATER, 
2014). Therefore, neurons serve as ideal latency sites, where the virus can persist lifelong 
in symbiosis with the host (LIU et al., 2001). Within ganglia, each sensory neuron is tightly 
wrapped in a sheath of laminar cells, representing the glial cells of the peripheral nervous 
system. These satellite glial cells (SGCs) are multifunctional nursing cells that regulate the 
neurons’ microenvironment and serve as physical support by forming a protective envelope 
around the neuron (HANANI, 2005). It has been shown that SGCs synthesize growth fac-
tors and proliferate following nerve trauma and malnutrition which presumably preserves 
the enclosed neuron (LEE et al., 1998; ELSON et al., 2003; VAN VELZEN et al., 2009). 
Similarly, SGC proliferation also has been detected in response to acute herpesvirus infec-
tions, which possibly prevents random virus spreading throughout the ganglia in a shield 
like manner (LAVAIL et al., 1997; ELSON et al., 2003). However, SGCs are very versatile 
in function and their roles during viral infection have just started to become elucidated. 
There is growing evidence that SGCs act as tissue-resident immune cells with phenotypic 
and functional similarities to antigen presenting cells (HANANI, 2005). As such, SGCs 
likely are involved in the innate immune response to herpesvirus infections in neurons: It 
has been shown that SGCs are activated during primary viral infection and can express 
cytokines/chemokines (IFN-α, IL-6, TNF-α, CXCL10) to orchestrate T-cell infiltration 
into the ganglia (HANANI, 2005; VAN VELZEN et al., 2009; OUWENDIJK et al., 2016; 
DEPLEDGE et al., 2018). This may highlight the importance of SGCs in clearing virus 
during acute infection/reactivation by them compensating the neurons insufficient ability 
to express viral antigens to the immune system (VERJANS et al., 2007; VAN VELZEN et 
al., 2009).  
Whether SGCs become infected productively during acute and/or serve as safe harbor dur-
ing latent infection is broadly (and somewhat controversially) discussed for HSV-1 and 
VZV (CROEN et al., 1988; WROBLEWSKA et al., 1993; LAVAIL et al., 1997; 
WILKINSON et al., 1999; CAI et al., 2002; LEVIN et al., 2003; HANANI, 2005; 
REICHELT et al., 2008; BERTKE et al., 2011; ZERBONI & ARVIN, 2016). While VZV 
infects and replicates efficiently in satellite cells using human DRG xenotransplantation 
models (REICHELT et al., 2008), satellite cells seem to be less susceptible for productive 
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HSV-1 infection using the same in vivo model (ZERBONI et al., 2013). Restrictive HSV-
1 viral replication in satellite cells has also been reported in other studies (WILKINSON et 
al., 1999; ELSON et al., 2003). Moreover, VZV can induce plasma membrane fusion be-
tween infected neuronal cell bodies and the surrounding satellite cells, resulting in rapid 
viral transfer from neuron to satellite cells and subsequent spreading to nearby neuron-
satellite cell complexes (REICHELT et al., 2008). During VZV reactivation, the rapid gan-
glionic spreading of reactivated virions increases the chances for anterograde axonal 
transport towards an entire area of the skin (dermatome), resulting in the typical derma-
tomal skin rash (WILKINSON et al., 1999; ZERBONI et al., 2013). Furthermore, the neu-
ronal damage post ganglionic spreading and signaling processes between neuron-satellite 
complexes have been associated with the characteristic neuropathic pain during VZV re-
activation, which is not common in HSV-1 infections (ZERBONI et al., 2013). Indeed, the 
phenomenon of ganglionic spreading could not be detected in HSV-1 reactivation and re-
current HSV-1 lesions are typically more focal and restricted to a single anatomical spot 
(SMITH, 2012; ZERBONI et al., 2013; BLOOM & DHUMMAKUPT, 2016).  
Numerous studies tried to define the precise cell location during HSV-1 and VZV latency 
within the neuron satellite complex of ganglia obtained during autopsy: While latent 
HSV-1 was consistently localized to neurons (CROEN et al., 1988; CAI et al., 2002; 
WANG et al., 2005a), some early VZV studies using in situ hybridization described VZV 
transcripts (CROEN et al., 1988; WROBLEWSKA et al., 1993) or DNA (LUNGU et al., 
1995) to be present in satellite glial cells during latency. However, this has been re-evalu-
ated later by laser capture microdissection (WANG et al., 2005a) and by cell separation of 
neurons and satellite cells prior to PCR evaluation (LEVIN et al., 2003). Both studies con-
cluded that the predominant cell type for VZV latency establishment is the neuron.  Nota-
bly, the low amounts of viral DNA and/or transcripts present during latency as well as the 
close proximity and interaction between satellite cells and neurons makes it quite challeng-
ing to consistently define the cellular localization of latent virus in ganglia 
(MAHALINGAM et al., 1999; LEVIN et al., 2003).  
3.3.3.2. T-lymphocyte immunity 
The virus-host coexistence during chronic persistent infection requires a precise balance 
between the dormant virus and the host immune system. In addition, this balance during 
latency must benefit not only the virus but also the host in order to be an evolutionary 
successful concept (SIMMONS & TSCHARKE, 1992; LEGER & HENDRICKS, 2011). 
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Within neurons, taming the virus in a non-lytic state is obviously an advantage for the host, 
as each reactivation leads to neuronal death which cannot be regenerated (LEGER & 
HENDRICKS, 2011; EGAN et al., 2013). It has been shown that CD8+ T-cells are in-
volved in maintaining the viral latent state by acting in a non-lytic way. They are therefore 
important host factors preserving the neuron and the (latent) virus (SIMMONS & 
TSCHARKE, 1992; LIU et al., 1996; LIU et al., 2000; KHANNA et al., 2003; VERJANS 
et al., 2007). Viral antigen during lytic- and low-level gene expression during latent infec-
tion may attract CD8+ T-cells via cytokines/chemokines that are most likely expressed by 
SGCs and to a lesser extent by neurons themselves (SIMMONS & TSCHARKE, 1992; 
HANANI, 2005; VAN VELZEN et al., 2009; OUWENDIJK et al., 2016; DEPLEDGE et 
al., 2018). Following antigen exposure, T-cells can differentiate to memory T-cells that 
remain permanently as virus specific memory T-cell and are ready to react with a fast re-
sponse in case of re-exposure. Memory T-cells can further be divided into (a) central 
memory T-cells, homing to lymphoid tissue; (b) effector memory T-cells, which are dis-
tributed to tissues in the periphery while constantly screening the environment for their 
specific antigen; and (c) tissue resident memory T-cells (TRM), a subset that typically re-
mains permanently guarding the primary infection site (EGAN et al., 2013). It has been 
speculated that following infiltration in to the ganglia during primary infection, CD8+ T-
cells remain in close proximity to neurons during latency probably for a life-time, forming 
a subset of CD8+ TRM (LIU et al., 1996; LIU et al., 2000; EGAN et al., 2013). Interestingly, 
CD8+ TRM do not provoke apoptosis of the infected neuron but suppress lytic gene expres-
sion via interferon-γ and granzyme B and therefore prevent reactivation (LIU et al., 2001; 
KHANNA et al., 2003; EGAN et al., 2013). Viral LATs and/or miRNA may stimulate the 
anti-apoptotic effect and therefore complete the balance of latency from the viral side 
(EGAN et al., 2013).  
An increased level of glucocorticoids during stress, hormonal imbalances or immunosup-
pression can disrupt this fine-regulated interplay from the host side by inhibition of CD8+ 
TRM function (EGAN et al., 2013; YU et al., 2018). Moreover, the immune regulation in 
the context of latency is likely more complex as previously thought and may also involve 
subsets of regulatory T-cells that control the cell count and function of CD8+ TRM (YU et 
al., 2018). However, the exact mechanisms of interaction between CD8+ TRM and latent 
virus is still poorly understood, and some authors even question their importance during 
latency (MOTT et al., 2016). Most of these studies mentioned above are based on HSV-1 
research in non-natural host (mice) models or in in vitro explant models. While these 
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models offer valuable research possibilities, they cannot mirror the highly coevolved adap-
tion between the virus and the natural host immune system. To truly understand the com-
plex balance of latency, it is essential to conduct studies in the natural host. Studying 
EHV-1 latency in the natural host therefore provides an excellent research model.  
Taken together, the virus is not able to truly “hide” lifelong from the host immune system 
during latency (KHANNA et al., 2004). The concept of latency rather involves host im-
munity and viral factors to establish a complex control mechanism which is then advanta-












Figure 1.: The fragile balance between viral and host factors during latency (modified 
from EGAN et al., 2013). Figure created with BioRender.com. 
Following entry into the neuronal nucleus, the viral genome circularizes (1) and associates 
tightly with cellular histones (2). While condensed forms of chromatin (2b) are involved in 
repressing lytic genes, active chromatin (2a) allows transcription of latency-associated tran-
script (LAT) promoter. LATs (3) supposedly promote silencing of lytic genes and support 
neuronal survival. Periodically, low-level lytic gene transcription (4) attracts T-cells possi-
bly through signals produced by satellite glial cells (SGCs). T-cells come in close contact 
with neuron and SGC (5) and can differentiate into tissue resident memory T-cells (TRM). 
TRM inhibit viral lytic gene transcription through interferon-γ (IFN-γ) and granzyme B 
(GrzB) (6). External stimuli (stress events or immunosuppression) or regulation by regula-
tory T-cells can inhibit TRM activity (7) which may result in higher transcription levels of 
lytic genes and a shift from latency to reactivation (8).  
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3.4. EHV-1 latency – status quo and statement of research purpose 
Aspects of EHV-1 latency are still not fully understood in detail and the predominant sites 
for latency establishment have been controversially discussed in literature (WELCH et al., 
1992; EDINGTON et al., 1994; SLATER et al., 1994; BAXI et al., 1995; CHESTERS et 
al., 1997; SMITH et al., 1998). Like all known Alphaherpesviruses, EHV-1 supposedly 
establishes latency in the TG during primary infection, where its persistence has been re-
peatedly confirmed (SLATER et al., 1994; BAXI et al., 1995; PUSTERLA et al., 2012). 
In addition, latent EHV-1 has been shown to persist in RALT and in circulating PBMCs 
(EDINGTON et al., 1986; WELCH et al., 1992; BAXI et al., 1995; CHESTERS et al., 
1997; SMITH et al., 1998). This is consistent with the lymphotropism of EHV-1 during 
acute infection resulting in viremia – an essential key feature for its pathogenesis which 
EHV-1 shares with its close relatives BoHV-1 and VZV. In early EHV-1 latency preva-
lence studies, presumably latent EHV-1 DNA was also detected in the spleen (WELCH et 
al., 1992; EDINGTON et al., 1994). This also has been reported for BoHV-1 latency 
(MWEENE et al., 1997) and further supports lymphotropism as an additional strategy for 
EHV-1 latency establishment.  
Our research group therefore hypothesized in a previous study that EHV-1 latency is not 
limited to TG and RALT and additional latency sites may exist (SAMOILOWA, 2019). 
Our aim was to analyze EHV-1 persistent infection 70 dpi in various lymphatic and neural 
tissues of three groups of horses: Group 1 was infected with neuropathogenic EHV-1 strain 
Ab4 (wildtype (WT)); group 2 with an EHV-1 polymerase mutant at position 752 (D > N; 
(Ab4 N742)); and group 3 with an EHV-1 glycoprotein D (gD), where gD of EHV-1 was 
replaced with gD of EHV-4 (Ab4 gD4). Horses of all groups were studied for 70 dpi, fol-
lowed by euthanasia and clinical data, nasal viral shedding and viremia are described in 
detail elsewhere (HOLZ et al., 2017; HOLZ et al., 2019).  
Consistent with VZV latency research, we detected EHV-1 DNA (via qPCR) not only in 
TG, but also in various sympathetic/parasympathetic ganglia of head, neck, thorax, abdo-
men, and in DRG (SAMOILOWA, 2019). This wide neural distribution of EHV-1 DNA 
beyond the period of viremia was confirmed in all three infection groups and was not re-
ported before. However, the important question whether EHV-1 is transported via neuronal 
or hematogenous route to these potential sites of latency remained unanswered.  
In addition, we could confirm that EHV-1 establishes latency in lymphatic tissue: EHV-1 
DNA was frequently detected in RALT and most importantly in abdominal mesenteric 
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lymph node and spleen. However, lymphotropism during latency was different among 
groups: While Ab4 WT and Ab4 gD4 established latency in respiratory (pharyngeal roof, 
mandibular, retropharyngeal lymph nodes) and in abdominal (spleen, mesenteric) associ-
ated lymph nodes, Ab4 N752 was significantly less lymphotropic for its latency establish-
ment (SAMOILOWA, 2019). Interestingly, horses in the Ab4 N752 group also showed 
significantly lower levels of viremia (HOLZ et al., 2017), which is consistent with in vitro 
studies, where N752 mutants are significantly less capable to infect monocytes following 
primary infection in the respiratory epithelium (VANDEKERCKHOVE et al., 2010). In 
contrast, Ab4 WT infected horses outnumbered the other groups in the magnitude of vire-
mia and Ab4 WT was more prone to establish latency in abdominal lymphatic tissue com-
pared to the other strain variants (HOLZ et al., 2017; SAMOILOWA, 2019).  
The consistent detection of chronic persistent EHV-1 infection in various neural and (ab-
dominal) lymphatic tissue samples together with differences in viremia and lymphotropism 
in latency establishment among the three infection groups suggested further investigation 
of the potential involvement of viremia in EHV-1 latency pathogenesis.  
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III. HYPOTHESIS AND OBJECTIVES 
The present study aims to further understand how EHV-1 is transported to abdominal neu-
ral tissue samples and which cells are predominantly latently infected at these locations. 
This information is crucial to understand the regulation and further define molecular as-
pects of EHV-1 latency pathogenesis. 
We hypothesize that EHV-1 latency is a dynamic state and time passed after primary in-
fection influences viral distribution and persistence. 
To address this hypothesis, we compare EHV-1 latency establishment between two groups 
of experimentally infected horses (EHV-1 strain Ab4, wild type) that were euthanized 
30 dpi (group 1) and 70 dpi (group 2). The main objectives of the present study are: 
i) Compare EHV-1 viral load and state of infection in neural and lymphatic tissue 
collected at day 70 pi with a timepoint closer to acute infection and 
viremia (30 dpi).  
ii) Determine the cellular localization of persistent EHV-1 within neural tissue by 
in situ hybridization (ISH) to further understand the molecular basis of EHV-1 
latency pathogenesis. 
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V. CONCLUSIONS AND FUTURE DIRECTIONS 
This dissertation aims to further the understanding of EHV-1 latency pathogenesis in the 
natural host. In two different study set-ups we detected presumably latent EHV-1 in a va-
riety of lymphatic and neural tissue samples at day 70 post experimental infection (pre-
study) (SAMOILOWA, 2019), and found differences in viral distribution, load and cellular 
localization when compared to a time-point closer to viremia (30 dpi) (GIESSLER et al., 
2020a). We overall conclude that EHV-1 latency is dynamic over time in its maintenance. 
Therefore, analyzing post-mortem tissue samples can only provide a “snapshot” of this 
complex state (DEPLEDGE et al., 2018). Most importantly, we could show that EHV-1 is 
present in non-neuronal cells within ganglia during latency, which is most likely attributed 
to infected T-cells and/or satellite glial cells. This work therefore refines the current 
knowledge of EHV-1 latency establishment in ganglia by hypothesizing that EHV-1 can 
use mononuclear cells during viremia as an additional hematogenous route towards neural 
latency locations.  
A more detailed characterization of the infected non-neuronal cell pool is now required to 
further investigate this hypothesis. For SVV, colocalization of virus and cell marker in a 
dual-immunofluorescence assay could prove the presence of infected T-cells adjacent to 
neurons (OUWENDIJK et al., 2013). Importantly, in this study the authors investigated 
acute infection and therefore used SVV nucleocapsid protein staining together with T-cell 
antibody staining for visualization (OUWENDIJK et al., 2013). During latency, where viral 
protein is usually not detectable, successful colocalization requires a combination of ISH 
(detection of viral genome or LAT) and IHC (detection of cell-type antigen). For HSV-1, 
this technique revealed that HSV-1 targets specific subsets of neurons for latency estab-
lishment by showing that LAT positive neurons (ISH) are predominantly characterized by 
a specific neuronal cell marker (IHC) (YANG et al., 2000). This method benefits from the 
fact that LAT is abundantly expressed during HSV-1 latency and readily detectable by ISH 
or RT-PCR (STEVENS et al., 1987; FRASER et al., 1992). Currently, there is a lack of a 
reliable marker (e.g. LAT) for EHV-1 latency and diagnostic approaches are somewhat 
limited as viral DNA is present in very low quantities during latency (MAHALINGAM et 
al., 1999; DUNOWSKA et al., 2015; KENNEDY et al., 2015; DEPLEDGE et al., 2018). 
This challenges diagnostic sensitivity (MAHALINGAM et al., 1999; DUNOWSKA et al., 
2015) and was probably the reason why first attempts to identify EHV-1 infected non-
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neuronal cells through a combined ISH (EHV-1 DNA)-IHC (CD3+ T-cells) double-stain-
ing assay failed in our laboratory.  
Future approaches that aim to further define EHV-1 latency may therefore consider includ-
ing high sensitivity methodology like Deep Whole Genome Sequencing and/or RNA se-
quencing. RNA sequencing is a powerful tool that finally allowed the discovery of the VZV 
LAT (DEPLEDGE et al., 2018). However, the direct sequencing of whole clinical or post-
mortem samples results in mixed host and viral nucleic acid sequences, with a significantly 
lower proportion of the latter (DEPLEDGE et al., 2011). The attempt to determine low 
abundant viral DNA/RNA within mixed host/virus deep sequencing results can be meta-
phorically speaking like searching for a needle in a haystack. It was not until the introduc-
tion of “target enrichment” followed by deep sequencing, before the VZV LAT could be 
detected (DEPLEDGE et al., 2018). In this approach, RNA “bait” probes were designed to 
hybridize with the VZV genome and separate viral nucleic acids prior to sequencing 
(DEPLEDGE et al., 2018). In a follow-up study of our recent findings we aim to further 
analyze EHV-1 transcripts during latency in neural (TG, ST) and lymphatic (RLn, MesLn) 
tissue samples at day 30 pi, using target (EHV-1) enriched RNA sequencing as previously 
described for VZV (DEPLEDGE et al., 2018).  
Defining transcripts that are consistently present during EHV-1 latency would provide us 
with a latency marker and allow to ultimately confirm abdominal neural and lymphatic 
latency locations for EHV-1. Furthermore, it would be interesting to investigate potential 
differences in the EHV-1 transcriptome during latency depending on the infected cell type 
(neuron vs. PBMC). It might be possible that viral gene expression and depth of latency 
differs between neurons and PBMCs as a result of the adaptation to the host cell environ-
ment. The capacity of EHV-1 to strongly adapt to PBMCs has already been described dur-
ing acute EHV-1 infection (LAVAL et al., 2015; POELAERT et al., 2019). In contrast to 
the lytic infection in epithelial cells, PBMCs are infected in an arrested manner, where 
replication is hampered (in monocytes) (LAVAL et al., 2015) or viral capsids are accumu-
lated (in T-cells) but “on standby” and not released until the target cells are reached 
(POELAERT et al., 2019). These strategies enable the virus to be transported effectively 
throughout the host body during viremia (LAVAL et al., 2015; POELAERT et al., 2019). 
The viral state in PBMCs may therefore hold an exceptional position during both acute and 
latent infection.  
On the host side of the balance of latency, the immune response is an important factor that 
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influences the depth of viral transcriptional silence and therefore needs to be further inves-
tigated in future studies. We can speculate that similar to what is known in HSV-1 and 
VZV latency, TRM and SGC may inhibit viral gene transcription by expressing cytokines 
(VAN VELZEN et al., 2009; EGAN et al., 2013; OUWENDIJK et al., 2016), but this has 
yet to be confirmed for EHV-1 latency. Interestingly, virus reactivation occurs more fre-
quently in older individuals, which is probably linked to age-related changes in the immune 
system (GRINDE, 2013). For example, it has been shown in humans that the proportion of 
regulatory T-cells increase in the elderly (LAGES et al., 2008; VUKMANOVIC-STEJIC 
et al., 2015), which was correlated to the reactivation of chronic persistent infectious dis-
ease (LAGES et al., 2008). The higher counts of regulatory T-cells lead to a decrease and 
functional inhibition of CD8+ T-cells in ganglia and therefore promote viral lytic gene 
transcription and reactivation (YU et al., 2018). Our research group is currently investigat-
ing the immune response of old and young horses following EHV-1 infection with the aim 
to determine host factors contributing to the pathogenesis of neurological disease. Using 
samples of this study setting, it would be interesting to characterize and compare the T-cell 
population in ganglia of old horses and young horses. IHC staining for regulatory T-cell 
(FoxP3+), CD8+ T-cell and CD4+ T-cell marker may provide valuable information on 
T-cell type/counts in correlation to viral load and transcriptional activity.  
While latency studies in the natural host are inevitable to involve the interaction of the host 
immune system, future studies may additionally consider in vitro approaches. An interest-
ing model has been recently described for HSV-1 and PsRV latency establishment in gan-
glia explants (RICHARDS et al., 2017). In this study, viral mutants were established with 
an impaired ability for retrograde axonal transport through a mutation of a viral transport 
complex protein. This eliminated latency establishment via neuronal pathway in vitro and 
in vivo (RICHARDS et al., 2017; PICKARD et al., 2020). As primary infection and repli-
cation remained potent the authors suggest that these mutants may be promising vaccine 
candidates for HSV-1, PsRV and other Alphaherpesviruses like EHV-1 (RICHARDS et 
al., 2017; PICKARD et al., 2020). Theoretically, similar EHV-1 mutants with impaired 
ability for infecting ganglia via neuronal pathway may be an interesting proof of concept 
approach for investigating neuronal infection via circulating PBMCs, using ganglia explant 
models as previously described (RICHARDS et al., 2017).  
Notably, all the conclusions of this dissertation are based on experimental infection studies 
with the neuropathogenic strain EHV-1 Ab4. Infections with EHV-1 Ab4 are known to 
result in a high magnitude of infected PBMCs and prolonged duration of viremia (ALLEN, 
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2008; HOLZ et al., 2017). Therefore, it is important to determine whether T-cell tropism 
during latency is a consistent strategy among other circulating EHV-1 strains and whether 
abdominal latency locations can be confirmed in random horse populations. For example, 
this could be investigated by tissue sample collection at slaughter and subsequent latency 
diagnosis. As we speculate that the EHV-1 DNA burden during latency might be below the 
detection limits of the recently applied methodology of qPCR, it might be worthwhile to 
consider the potential advantages of technological advancements in the field of PCR. 
Digital PCR (dPCR) is a new emerging PCR technology in clinical virology diagnostics 
(SALIPANTE & JEROME, 2019). Like qPCR, dPCR is based on primer/probe binding on 
target sequences followed by amplification and detection by fluorescence. However, for 
dPCR, the sample is not assayed in a homogenous solution but divided into many separate 
sub-reactions, for example by oil microdroplets (droplet digital PCR) (SEDLAK et al., 
2014). This guarantees an isolation of few target sequences in a single micro-reaction 
which results in higher target concentration. Therefore, dPCR is thought to outperform 
qPCR in precision and is less affected by PCR inhibitors that are present in certain (tissue) 
samples (QUAN et al., 2018; SALIPANTE & JEROME, 2019). Following analysis of the 
micro-reactions the absolute quantification of target concentration can be calculated with-
out extrapolation to a standard curve which simplifies quantification especially for rare 
target sequences. One limitation of dPCR is the smaller total reaction volume compared to 
qPCR, resulting consequently in a smaller input volume of sample (QUAN et al., 2018). 
This might lead in some assays to a lower sensitivity of dPCR (QUAN et al., 2018). How-
ever, the detection sensitivity of dPCR is controversially discussed in literature (KOEPFLI 
et al., 2016; VERHAEGEN et al., 2016; SALIPANTE & JEROME, 2019) but seems over-
all to be comparable to qPCR (KELLEY et al., 2013). As dPCR has been used in HSV-1 
research to detect latent HSV-1 genome in ganglia (AUBERT et al., 2014; AUBERT et al., 
2016; BAIRD et al., 2018), it might be a promising approach for EHV-1 latency diagnosis. 
After all, it is critical to evaluate the potential advantages of dPCR for each specific assay 
(and sample type), as it is currently an expensive alternative to qPCR.   
Overall, this dissertation provides novel insights in EHV-1 latency pathogenesis, draws 
conclusions on EHV-1 latency regulation in ganglia and opens up interesting directions for 
future studies. It still must be determined whether EHV-1 uses its lymphotropism during 
viremia for reaching as many safe neural latency harbors as possible or whether this hap-
pens “by accident” while travelling to the CNS/uterus endothelium. However, from an evo-
lutionary point of view, creating multiple locations for hiding its genome may be of greater 
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benefit for EHV-1 than causing disease manifestation and potential death of the host. From 
this perspective, one might speculate that EHV-1 causes fatal disease manifestation fol-
lowing viremia “by (dreadful) accident” while paving its way for latency establishment and 
actually aiming for its persistence in the host and thus in the equine population.  
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VI. SUMMARY 
Characterizing viral distribution, viral load and cell tropism during early latent 
Equid Herpesvirus 1 (EHV-1) infection: novel insights into EHV-1 latency 
pathogenesis  
Equid Herpesvirus 1 (EHV-1) is an important ubiquitous Alphaherpesvirus that infects 
horses worldwide. It causes respiratory disease, equine herpesvirus myeloencephalopathy 
(EHM), abortion and neonatal foal death. Primary EHV-1 infections of the upper respira-
tory tract epithelium (URT) typically result in a peripheral blood mononuclear cell-associ-
ated viremia. This transports the virus through the body toward the vascular endothelium 
of the central nervous system (CNS) or the pregnant uterus, where it can lead to severe 
disease manifestations (EHM, abortion). During or shortly after primary infection, EHV-1 
also establishes a chronic persistent infection in the host. This important strategy of all 
herpesviruses is called latency and symbolizes a non-productive state of infection which is 
characterized by repression of viral lytic gene expression. Latency ensures the viral persis-
tence in the host population, as periodical reactivation events can lead to viral spread and 
ultimately to new outbreaks. As there is currently a lack of fully protective EHV-1 vac-
cines, understanding the pathogenesis and maintenance of EHV-1 latency becomes of ut-
most importance for the development of potential defense strategies. As the respiratory 
tract is the primary site of infection, it is thought that EHV-1 infects sensory nerve endings 
during initial infection and subsequently establishes latency in the trigeminal ganglia (TG). 
Moreover, respiratory tract-associated lymphoid tissue (RALT) and peripheral blood mon-
onuclear cells (PBMCs) have been described as additional latency locations. Beyond that, 
our research group recently proposed that EHV-1 can persist additionally in a variety of 
sensory, sympathetic and parasympathetic ganglia of the head, neck and abdomen as well 
as in abdominal lymphoid tissue. Therefore, the present study aims to follow-up and to 
further characterize EHV-1 transportation toward latency locations and its cell tropism dur-
ing latency in vivo.  
Two separate groups of yearling horses were experimentally infected intranasally with 
EHV-1, strain Ab4, and euthanized 30 days post infection (dpi), (n = 9) or 70 dpi (n = 6), 
respectively. During necropsy, TG, sympathetic trunk (ST), retropharyngeal and mesen-
teric lymph nodes (RLn, MesLn) and kidney samples (control) were collected. Viral DNA 
load was determined by quantitative PCR (qPCR) in the respective tissue samples and re-
sults were compared between the two infection groups (30 dpi, 70 dpi). Furthermore, a 
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given sample was defined as latently infected when EHV-1 DNA was detected (via qPCR), 
while the EHV-1 late gene glycoprotein B reverse transcriptase PCR (RT-PCR) and im-
munohistochemistry (IHC) results for viral protein were consistently negative. Neural tis-
sue samples were further evaluated for the presence of histopathological changes and in-
flammatory infiltrates were characterized by IHC staining against CD3 (T-lymphocytes, 
(T-cell)) and CD20 (B-lymphocytes, (B-cell) antigen and differentiated from satellite glial 
cells by S-100 IHC staining. Finally, selected EHV-1 DNA positive neural tissue samples 
were further analyzed by in situ hybridization (ISH, RNAScope®) to determine the cellular 
localization of persistent EHV-1.  
EHV-1 DNA was detected in TG, ST, RLn, and MesLn samples in horses 30 and 70 dpi. 
Lytic infection was excluded in the present study as neither of the samples were positive 
for EHV-1 late gene gB mRNA or viral protein. When comparing horses 30 and 70 dpi, a 
decrease in the number of positive TG, RLn and MesLn samples was observed. In addition, 
the viral copy number in TG and RLn declined significantly from 30 to 70 dpi. Histopatho-
logical evaluation revealed mild inflammation in all neural tissue samples and IHC identi-
fied CD3+ T-cells as the main proportion of inflammatory infiltrates adjacent to neuronal 
cell bodies. Notably, EHV-1 ISH signal in ganglia 30 dpi was not only located in the neu-
rons of TG and ST, but also in non-neuronal support/interstitial cells surrounding the neu-
ron. In contrast, the neuron was the sole cell type showing distinct EHV-1 signal in TG 
70 dpi. For ST samples 70 dpi, EHV-1 ISH signal was sporadically detected in the cyto-
plasm of the neurons but also in adjacent non-neuronal cells.  
Overall, this dissertation reports consistent detection of latent EHV-1 DNA in a variety of 
lymphatic and neural tissue samples and differences in viral distribution, viral load and 
cellular localization when evaluated at two different time-points during early EHV-1 la-
tency. The differences in findings over time highlight that latency is a dynamic state and 
the analysis of post-mortem tissue samples may only allow us to make conclusions for this 
particular “snapshot” of latency. Most importantly, the distinct non-neuronal cellular lo-
calization proposes that EHV-1 may use T-cells as cellular vehicle during viremia toward 
potential latency locations. This may symbolize an additional, hematogenous route for la-
tency establishment besides the well described neuronal pathway and highlights a striking 
similarity between EHV-1 and its close relative human pathogen Varicella Zoster Virus.   
 
This study was made possible through a grant by the Grayson Jockey Club Research 
Foundation, Inc., Lexington, KY.
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VII. ZUSAMMENFASSUNG 
Virusverteilung, Viruslast und zelluläre Lokalisation im Pferd während der frühen 
Latenzphase einer Equiden Herpesvirus 1 (EHV-1) Infektion: neue Erkenntnisse zur 
Pathogenese der EHV-1 Latenz  
Infektionen mit dem Equiden Herpesvirus 1 (EHV-1) führen zu respiratorischen Erkran-
kungen, Rückenmarkserkrankungen (Equide Herpesvirusmyeloenzephalopathie (EHM)) 
und Aborten und stellen durch die hohe Virus Prävalenz innerhalb der Familie der Equidae 
weltweit eine ernsthafte Bedrohung für domestizierte sowie wildlebende Einhufer dar. 
Während der primären Infektion der oberen Atemwege wird das Virus nach einer initialen 
Vermehrung in lokale Lymphknoten transportiert und gelangt von dort anschließend in die 
Blutbahn. Auf diesem Weg der Virämie kann sich das Virus im gesamten Körper ausbrei-
ten und Gefäßendothelien von Rückenmark oder Uterus erreichen. Neben diesem akuten 
Infektionsverlauf verfügt EHV-1 über die Fähigkeit zur Ausbildung einer chronisch per-
sistierenden Infektion. Daher stehen am Anfang oftmals verheerender EHV-1 Ausbrüche 
meist reaktivierende „Reservoir-Tiere“, die das Virus nach überstandener Infektion in sich 
beherbergen. Diese Schlüsselstrategie aller Herpesviren, nach initialer Infektion in be-
stimmten Geweben (üblicherweise Zellen des Immun- oder des Nervensystems) in einen 
Ruhezustand zu fallen und weitgehend unentdeckt vom Immunsystem des Wirtes auf un-
bestimmte Zeit zu überdauern, wird als Latenz bezeichnet. Während dieser „Schlummer-
phase“ persistiert das virale Genom im Kern infizierter Zellen, ohne sich zu replizieren und 
ohne sogenannte lytische Gene zu exprimieren, die für die Produktion eines vollwertigen, 
infektiösen Virions notwendig sind.  
Es ist wenig über die Umstände und Faktoren bekannt, die den Balanceakt der Latenz be-
einflussen und in Richtung der lytischen Genexpression und damit der Reaktivierung ver-
schieben. Da aktuell verfügbare Impfstoffe eine Infektion und Erkrankung nur mäßig ef-
fektiv zu verhindern vermögen, ist es essenziell, die Pathogenese der Latenz besser 
verstehen zu lernen, um künftig Abwehrstrategien entwickeln zu können. Basierend auf 
den Erkenntnissen früher Studien in den 1990er Jahren, wird bis heute vermutet, dass 
EHV-1 im Zuge der initialen Infektion die Axone des Nervus trigeminus infiziert und Neu-
rone des Ganglion trigeminale (TG) sowie zusätzlich regionale Lymphknoten der oberen 
Atemwege als Rückzugsgebiete für die Phase der Latenz heranzieht. Unsere Forschungs-
gruppe konnte vor Kurzem ergänzend aufweisen, dass EHV-1 vermutlich in weitaus mehr 
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neuralen und lymphatischen Geweben persistiert als bisher angenommen (SAMOILOWA, 
2019): Zu einem Zeitpunkt von 70 Tagen nach experimenteller Infektion, konnte EHV-1 
DNA in einer Vielzahl von sensorischen, sympathischen und parasympathischen Ganglien 
sowie in respiratorischen und abdominalen lymphatischen Geweben nachgewiesen wer-
den.  
Um die Pathogenese der latenten EHV-1 Infektion besser verstehen zu können, war das 
Ziel der vorliegenden Dissertation, das virale Verteilungsmuster, die Viruslast und die zel-
luläre Lokalisation zu zwei verschiedenen Infektionszeitpunkten zu vergleichen. Hierfür 
wurden zwei Gruppen von Pferden mit EHV-1 Wildtyp Stamm Ab4 intranasal infiziert und 
30 (n = 9) respektive 70 (n = 6) Tage nach Infektion euthanasiert. Während der Sektion 
wurden TG, Truncus sympathicus (Grenzstrang) (ST), Lymphonodi (Lnn.) 
retropharyngeales (RLn) und Lnn. mesenteriales (MesLn) und Niere (als Kontrollorgan) 
entnommen. Anschließend wurden die Gewebe beider Infektionsgruppen mittels quantita-
tiver PCR (qPCR) auf EHV-1 DNA untersucht. Eine Probe wurde als latent infiziert defi-
niert, wenn EHV-1 DNA nachgewiesen, jedoch gleichzeitig das Auftreten von sowohl ly-
tischer (Glykoprotein B (gB)) mRNA (mittels Reverse Transkriptase PCR) als auch 
lytischem Protein (gB) (mittels Immunhistochemie (IHC)) ausgeschlossen wurde. Des 
Weiteren wurden Nervengewebeproben auf histopathologische Veränderungen untersucht 
und entzündliche Infiltrate mithilfe von IHC Färbung gegen CD3-Antigen (T-Lymphozy-
ten (T-Zellen)) und CD20-Antigen (B-Lymphozyten (B-Zellen)) weiter charakterisiert und 
von neuronalen Stützzellen (Satellitenzellen) (IHC gegen S-100 Antigen) abgegrenzt. Um 
schließlich die zelluläre Lokalisation von persistierendem EHV-1 zu bestimmen, wurden 
ausgewählte EHV-1 DNA positive Nervengewebeproben zusätzlich mittels In-Situ-Hybri-
disierung (ISH, RNAScope ®) analysiert.  
Sowohl 30 als auch 70 Tage nach Infektion konnte EHV-1 DNA in TG-, ST-, RLn- und 
MesLn- Proben nachgewiesen werden. Zudem wurde eine lytische Infektion nach gegebe-
ner Definition konsistent ausgeschlossen. Die Anzahl EHV-1 positiver TG-, RLn- und 
MesLn- Proben nahm über den Zeitraum von 30 auf 70 Tage nach Infektion ab. Zusätzlich 
wurde ein signifikanter Rückgang der Viruslast in TG- und RLn-Proben von 30 auf 
70 Tage nach Infektion beobachtet. Die histopathologische Auswertung ergab milde ent-
zündliche Veränderungen in allen Nervengewebeproben, wobei CD3+ T-Zellen den 
Hauptanteil der entzündlichen Infiltrate ausmachten und häufig unmittelbar angrenzend zu 
neuronalen Zellkörpern zu finden waren. Insbesondere wurde virale DNA zum Zeitpunkt 
30 Tage nach Infektion mittels ISH nicht nur in den Nervenzellkörpern eines Ganglions 
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(TG und ST) nachgewiesen, sondern auch in den umliegenden nicht-neuronalen Zellen 
(Satellitenzellen und/oder Lymphozyten). In den TG-Proben 70 Tage nach Infektion war 
das EHV-1 Signal dagegen nur im neuronalen Zellkörper nachzuweisen. Bei ST-Proben zu 
diesem Zeitpunkt konnte nur vereinzelt positives Signal im neuronalen Zytoplasma sowie 
in den angrenzenden nicht-neuronalen Zellen festgestellt werden.  
Zusammenfassend beschreibt die vorliegende Dissertation einen konsistenten Nachweis 
latenter EHV-1 DNA in einer Vielzahl von neuralen und lymphatischen Geweben, einen 
Unterschied in Viruslast und Verteilung zwischen beiden Infektionsgruppen sowie ein ein-
deutiges EHV-1 Signal in Satellitenzellen/Lymphozyten angrenzend zu neuronalen Zell-
körpern. Diese Ergebnisse lassen schlussfolgern, dass die Latenz ein durchaus dynami-
sches Stadium darstellt und die post-mortem Analyse von Gewebeproben daher nur eine 
Momentaufnahme ermöglichen kann. Gleichwohl deutet der hier dargebotene Einblick in 
die EHV-1 Latenz darauf hin, dass EHV-1 möglicherweise neben dem neuronalen Trans-
port auch den lymphozytären Transport während der Virämie nutzt, um weitere 
Latenz-Lokalisationen zu erreichen. Damit würde die Pathogenese der latenten EHV-1 In-
fektion weniger, wie bisher angenommen, derjenigen des Herpes Simplex Virus 1 entspre-
chen, sondern vielmehr derjenigen des Varizella Zoster Virus.  
 
Die vorliegende Studie wurde unterstützt durch einen Förderbeitrag der „Grayson Jockey 
Club Research Foundation, Inc., Lexington, KY“. 
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